NCT06990984Phase 2Not yet recruiting

A Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum (LSS)

Study sponsor: Thiogenesis Therapeutics, Inc.

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-06Estimated
Enrollment · participants18Estimated
Source updated2026-07-24Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Primary completion date changed

Before: Sep 2026. After: Jun 2027.

Check registry source